Search Results

BioMatrix Specialty Infusion Pharmacy (“BioMatrix” or “The Company”) announced today the sale of the majority interests of the company from Acon Investments & Triton Pacific Healthcare to Frazier Healthcare Partners (“Frazier”).

BioMatrix Specialty Pharmacy is pleased to announce the appointment of Ted Kramm to the Board of Directors.

Elutia Inc. (Nasdaq: ELUT) today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its next-generation drug-eluting biomatrix product, CanGarooRM®.

Ansys (NASDAQ: ANSS) today announced that it is adopting NVIDIA Omniverse application programming interfaces (APIs) to offer 3D-IC designers valuable insights from Ansys’ physics solver results through real-time visualization.

BioMatrix Specialty Pharmacy announced the organization has been recognized with a fifth consecutive “Best and Brightest Companies to Work For in the Nation” award.

MCRA, the leading privately held independent medical device, diagnostics, and biologics Clinical Research Organization (CRO) and advisory firm is pleased to announce its role in the U.S. Food and Drug Administration’s (FDA) 510(k) clearance for 3D Systems’ 3D-printed, patient-specific cranial implant solution — VSP® PEEK Cranial Implant.

ZSFab Inc., a leading expert in digitally structured materials and 3D printed orthopedic devices, proudly announces the first clinical utilization of its recently launched InterConnect™ 3D Printed Ti Lumbar Interbody System.

Stratasys Ltd. and Ricoh USA, Inc. announced the enrollment of the first patient in a groundbreaking clinical study aimed to evaluate the use of 3D printed models for orthopedic oncology.

Ricoh USA, Inc. and Stratasys Ltd. (NASDAQ: SSYS) today announced the enrollment of the first patient in a groundbreaking clinical study aimed to evaluate the use of 3D printed models for orthopedic oncology.

Predictive Oncology Inc. today announced the availability of its unique 3D cell culture model to advance cancer drug discovery and enable future drug development.